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Glaucoma is a progressive, chronic optic neuropathy characterized by a typical visual field defects. Four main classes of topical
medication are actually available on the market: beta-blockers, prostaglandins, alpha2-agonists, and topical carbonic anhydrase
inhibitor to treat intraocular pressure (IOP). +e aim of this review is to outline the efficacy of timolol and to evaluate the impact of
this treatment on patients’ quality of life. Among beta-blockers, timolol is most used at three different concentrations: 0.1%, 0.25%,
and 0.5%. While the first one is a gel, the other two products are solution. Timolol has few topical side effects, while it has some
important systemic side effects on the cardiac and respiratory systems. +e balance between efficacy and safety is always the main
aspect to care patients. Because of the less efficacy of timolol 0.1% solution, the possibility to use carbomers as vehicle in the gel drops
helped timolol 0.1 to be used in clinics, extending the time contact between the active ingredient and the surface of the cornea. Using
preservative-free timolol 0.1 for treatment, IOP was at the same level of the other beta-blockers at higher concentration, but it was
better tolerated. Preservative-free treatment improved the quality of life reducing dry-eye like symptoms; furthermore, the presence
of an artificial tear in the medication bottle could help adherence. +e once daily dosing improves compliance.
1. Introduction
+e intraocular pressure (IOP) is determined by the balance
of aqueous humor production and drainage. While pro-
duction occurs via the ciliary body, drainage occurs pre-
dominantly (50–75%) through the trabecular meshwork and
secondarily (25–50%) through the ciliary muscle, supra-
ciliary space, suprachoroidal space, and sclera (uveoscleral
outflow). [1–3] Within the general population, the distri-
bution of “normal” IOP is almost Gaussian except for a slight
skew toward higher pressures. +e mean value is approxi-
mately 15mmHg, and two standard deviations to either side
of the mean give a “normal” range of approximately 10–
20mmHg. However, the concept of normal or abnormal
IOP value is mainly theoretical except for the high values,
and any IOP value could be pathological for a given optic
nerve head (ONH) [1–3]. 24 hour variations in IOP are
mainly due to variation in aqueous humor production [4],
and this process is principally regulated by sympathetic
system; in fact, catecholamines that are secreted by adrenal
medulla induce the aqueous humor production following a
24 hour cycle, and their level monitored with urine secretion
falls down during the sleep phase [5].
In healthy subjects, IOP variations are characterized by a
diurnal average that is lower than the nocturnal; in this case,
the 24 hour-IOP curve takes the shape of a sine curve and the
dimension of variation is around 3–6mmHg; in particular,
clearance of aqueous humor during sleep is reduced by half
compared to the first hour after waking [5, 6]. On the
contrary, in glaucomatous patients, the 24 hour variations
can reach up to 18mmHg with the inversion of the circadian
rhythm, with the average value higher during the day with a
characteristic peak in the morning and a nocturnal IOP
reduction lower than in healthy subjects [4–9].
Under the clinical term of glaucoma, there are different
conditions with the common feature of an optic neuropathy
characterized by a distinctive loss of retinal nerve fiber layer
(RNFL) and optic nerve head (ONH) defects. +e loss of
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retinal ganglion cells can lead to an irreversible loss of visual
field, usually beginning paracentrally, but becoming com-
plete if the disease is uncontrolled. +e only risk factor that
we can modify is the IOP, and IOP modification is possible
by using topical drops [10].
Four main classes of topical medication are actually
available in the market: beta-blockers, prostaglandins,
alpha2-agonists, and topical carbonic anhydrase inhibitor
(CAI). Among these four classes, beta-blockers are the oldest
one. Beta-blockers are still one of the classes most used by
glaucoma patients, whether in monotherapy or combined
therapy. Over 40% of glaucoma or hypertensive patients are
on beta-blockers, and nearly one out of every two new
patients receives a beta-blocker as a first line therapy, usually
timolol.
1.1. Beta-Blockers. +ey lower IOP level acting on beta-
adrenergic receptors located on the nonpigmented ciliary
epithelium and on vessels, thereby limiting active transport
of aqueous humor, thus reducing the production; in
long-term treatment, the secretion can fall by 40 to about
50 %. Also, vascular mechanism that reduces the passive
generation of aqueous by ultrafiltration may be involved.
Timolol’s blocking action is powerful, nonselective β1-β2,
lipophilic (essential property for penetrating the cornea,
except for carteolol) without any type of membrane-
stabilizing activity [11].
In the market, three different concentrations of topical
timolol are available, which are 0.1%, 0.25%, and 0.5%.
While the first one is a gel, the other two products are
solution. Timolol has few topical side effects, while it has
some important systemic side effects on the cardiac and
respiratory systems. +e balance between efficacy and safety
is always the main aspect to care patients.
Because of the less efficacy of timolol 0.1% solution, the
possibility to use carbomers as vehicle in the gel drops
helped timolol 0.1 to be used in clinics, extending the contact
time between the active ingredient and the surface of the
cornea. Carbomers are polymers created by cross-linking
acrylic acid with ethers in the presence of an organic solvent.
+ese macromolecules create a three-dimensional net-
work able to keep a huge quantity of water in their mesh
(about 1000 times their dry volume). For this property, an
aqueous, stable, transparent, colorless, nonsticky gel is so
required.
Carbomers are particularly appropriate for ophthalmic
use for some peculiar properties:
(i) +eir viscosity decreases very rapidly, so they can
cover entirely the surface of the eye
(ii) +ey instantly restore when eyelids are open for
their rheological properties
(iii) +ey do not run when placed on a slope, and this is
particularly useful for a well coverage of the entire
eye
(iv) +eir dissolution is very gradual because they sta-
bilize with mucous layer glycoproteins of the tear
film
+e principal reason for prolonged ocular contact time is
represented by carbomer’s mucoadhesive properties while
viscosity plays only a minor role [12]. Carbopol 974P is the
carbomer used for timolol 0.1% gel (TimoGel 0.1%,+ea), in
which the solvent is ethyl acetate instead of benzene com-
monly used in other ophthalmic gels. +e clearance of an
ophthalmic solution measured by radioisotopes depends
only in part on viscosity; as a matter of fact, carbopol and
polyvinyl alcohol (PVA) have the same viscosity, but re-
sidual corneal activity after one hour from instillation is
higher for the first one, but both agents are however superior
to a simple solution [13].
+e viscosity of pure carbomer often causes blurred
vision for several minutes after administration; that is why
TimoGel 0.1% is used, which is a gel obtained by the
combination of PVA and carbopol that spreads quickly over
the surface of the eye, also maintaining the mucoadhesive
properties of a carbomer. +is structure is also used to
vehicle the gradual release of timolol in the eye [12–14].
Carbomers have the benefit of staying for a prolonged
time over cornea and conjunctiva surface, while other liquid
gels have a residence time comparable to solutions. It is
widely demonstrated through scintigraphic studies of cor-
neal contact time that a standard saline solution disappears
in less than 20minutes from the surface of the eye, while a
mucoadhesive gel stays for over 40minutes after the in-
stillation at an acceptable quantity [14].
Several studies have already confirmed that use of
carbomers have become the first-choice therapy for patients
who suffer from dry eye disease increasing tear break-up
time (BUT) and improving Schrimer’s test results, also in
healthy patients [15–17].
Carbomers are often used as vehicle the gradual release
of various active agents for instance 2% pilocarpin (12–14).
+e concentration of an active agent combined with a
carbomer gel is significantly higher when the same in-
gredient is instead combined with a standard solution [18].
1.2. Ocular and Systemic Pharmacodynamics of Timolol Gel.
+e elimination half life of timolol on the eye surface is about
100 times longer when the vehicle is a carbomer gel than
when it is a simple saline solution and 10 times longer than a
viscous gel of hydroxyethylcellulose; in this way, carbomers
extend bioavailability and increase absorption of active
agents [19].
It is well demonstrated in animal studies that measurable
levels of timolol are found one hour after administrating
0.1% gel formulation instead of 0.5% timolol solution that
disappears in about half an hour [20]; in fact, local pene-
tration of gel formulation is 2.6 to 3.1 times greater than the
0.5% timolol solution [19].
A study performed on rabbits showed that a gel for-
mulation with half concentration of timolol (0.05%) had
peak concentration in the aqueous humor that was three
times higher than a conventional 0.1% timolol solution [21].
In addition to this, when the beta-blocker arrives in the
aqueous humor, it spreads on the tissue of the anterior
segment and in particular in the granules of melanin in the
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ciliary body, allowing a gradual release of the active principal
ingredient and improving its bioavailability in the receptor
sites [11]. In humans, when compared to a 0.5% timolol
solution, it is demonstrated that TimoGel 0.1% reduces the
dose and the frequency of administration while maintaining
the same therapeutic efficacy [22–37].
+e systemic absorbance of timolol when administered
by topical ocular instillation is rapid and occurs principally
through the nasopharyngeal tract [19]. +e feasible adverse
events are related to the dose of exposition and to the plasma
concentration of beta-blockers, this possibility increases
rapidly after the threshold of 200 pg/ml [38].
When a single dose of 0.2mg of timolol is administered
either intravenously or by topical ocular instillation, plasma
concentration is reached immediately with intravenous
administration, whereas for topical use, plasma concentra-
tion is reached about 24minutes after instillation of the
topical agent, and its peak plasma concentration is about 4
times lower than that obtained with intravenous adminis-
tration [38].
In comparison to ocular instillation, oral administration
of a single dose of 20mg of timolol causes a concentration 72
times higher than that produced by the common ocular
topical preparation [39]. While the absorption of topical
timolol into the systemic circle is lower than that in oral
assumption, the mean systemic absorbance of timolol in
ocular instillation is about 78%, so the systemic side effects
are less evident than those with oral administration but still
present [40, 41].
Timolol in gel formulation permits a lower concentra-
tion and a slower release of active agents to obtain systemic
kinetics similar to those of oral administration. A French
study was performed to compare systemic absorption of
three types of formulation of timolol eye drops: 0.1% timolol
maleate gel, 0.5% timolol aqueous solution, and 0.5% timolol
maleate gel [42].
Maximum plasmatic concentration (Cmax) was signifi-
cantly (p � 0.0003) lower with timolol 0.1% gel than that
with timolol 0.5% aqueous solution after both the first in-
stillation and two weeks of treatment. Its mean plasma
concentrations did not exceed 0.10 ng/mL after instillation
of timolol 0.1% gel at either time-point measured, but they
reached 0.80 ng/mL and 0.66 ng/mL after two weeks of
treatment with timolol 0.5% aqueous solution and 0.5% gel,
respectively. +e areas under the concentration-time curve
(AUC) values were 15 to 38 folds higher after ocular ad-
ministration of 0.5% preparation than those after admin-
istration of 0.1% gel. After timolol 0.5% aqueous solution
treatment, mean half-life (t 1/2) was approximately 3 h 30 m,
while it was approximately 4 h 30 m after timolol 0.5% gel;
for timolol 0.1% gel, t 1/2 was not obtained because toomany
values were below the lower limit of assessment [42]. After
instillation of 0.1% maleate gel, its Cmax was reduced by
almost 90% compared to concentrations obtained after
instillation of both 0.5% aqueous solution and 0.5% gel.
Between 0 and 12 hours postadministration, AUCs were also
reduced by up to 93 to 98%. In all patients, after 8 h or 24 h
0.1% from maleate gel instillation, timolol could not be
quantified in the plasma [42].
+e three essential factors to consider when prescribing a
glaucoma therapy are efficacy, tolerance, and quality of life of
patients.
2. Clinical Efficacy
Several studies have already demonstrated the efficacy of
timolol in treating glaucomatous patients; in fact, in long-
term therapy, IOP falls down from 27 up to 35% of its
original value; the mechanism of action is essentially due to
the reduction of aqueous humor production more for ti-
molol than that for other beta-blocker agents such as car-
teolol or betaxolol [23, 24, 41].
2.1. Efficacy of a Single Dose of 0.1% Timolol Gel in Healthy
Volunteers. Two clinical studies comparing the 0.1% timolol
gel to 0.5% timolol solution in healthy volunteers have
shown that there was a IOP reduction of 30% at peak
compared to the baseline, with an equivalent decreasing
curve for both products [31, 43]. +e similar efficacy profile
of IOP-lowering effect of 0.1% timolol in gel compared to a
0.5% timolol solution in healthy volunteers was confirmed
also in a recent French study [42].
2.2. Timolol 0.1% Gel vs Timolol 0.5% Solution in Glaucoma
Patients. A prospective, randomized, cross-over study in-
vestigated the circadian intraocular pressure and blood
pressure (BP) reduction obtained with timolol maleate 0.5%
solution administered twice daily versus timolol 0.1% in gel-
forming carbomer administered in the morning in patients
with primary open-angle glaucoma (POAG). Both timolol
formulations showed the same 24-hour-IOP efficacy profile
with a once-a-day and well-tolerated administration for the
formulation in gel [27].
Furthermore, in different studies, when administered in
monotherapy, 0.1% timolol gel reduces IOP by 27%
(p< 0.001) [22–33], comparable to a conventional 0.5%
timolol solution and superior to a 0.1% timolol solution
(p< 0.001) [37].
+erapeutic efficacy of 0.1% timolol gel in patients with
POAG or Ocular Hypertension (OH).
All the published studies on the efficacy of 0.1% timolol
gel have demonstrated an efficacy at least comparable to
benchmark treatments [22, 32–37] (Table 1).
2.3. Efficacyof 0.1%TimololGel as a Substitution for aPrevious
7erapy. A recent study confirmed that the use of
preservative-free gel of timolol 0.1% once daily maintained
the efficacy on IOP and reduced signs and symptoms in
almost all glaucomatous patients treated by preserved
latanoprost with signs of intolerance. On the basis of all these
experimental and clinical reports, it should be recommended
to use benzalkonium-free eye drops whenever possible,
especially in patients with prolonged treatments, in those
suffering from preexisting or concomitant ocular surface
diseases, and those experiencing side effects related to the
ocular surface [44, 45].
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2.4. Efficacy of Timolol as an Adjunctive 7erapy. Timolol
works in synergy with the other classes of drugs currently
prescribed in glaucoma, namely, CAIs and prostaglandins.
Prostaglandin agonists (latanoprost, bimatoprost, and
travoprost) act by increasing uveoscleral outflow. +eir
combination with beta-blockers has an additional effect on
IOP [29, 44–46]. +e combination of 0.1% timolol gel and
latanoprost results in an overall IOP reduction of 38%
(p< 0.012). +e administration of a dual therapy of timolol
and travoprost in patients with an average pretreatment IOP
of 25 to 27mmHg results in a reduction to 16-17mmHg, an
average reduction of 8 to 10mmHg (32 to 38%) [41].
After two weeks on timolol or latanoprost alone, IOP
was reduced to around 18-19mmHg; the combination of
timolol and latanoprost resulted in an additional significant
IOP reduction (p< 0.01) of 13 to 14% in comparison to each
treatment used alone.+is allowed an IOP of 15 to 16mmHg
to be attained [29], while the combination of bimatoprost or
travoprost with timolol results in an additional IOP re-
duction of around 5 to 7mmHg [45, 46].
Topical CAIs reduce production of aqueous humor by
directly inhibiting carbonic anhydrase in ciliary processes.
+eir combination with timolol results in an additional
reduction of around 17% for dorzolamide and brinzola-
mide [47].
2.5. Timogel and FixedCombination vs UnfixedCombination.
Reducing the number of drugs is known to promote
compliance and generally improve local tolerance by de-
creasing the quantity of preservative. Moreover, the suc-
cessive administration of two lots of eye drops leads to the
secondmedication washing the first, with a dilution of 45% if
patients wait only 30 seconds and of 17% if they wait two
minutes. +e ideal interval of at least five minutes is rarely
respected [48]. +ese considerations have led to the devel-
opment and launch of fixed combinations, particularly with
timolol, as a way of avoiding the disadvantages of dual
therapies. However, in order to act on the morning IOP
peak, timolol needs to be administered in the morning as its
peak efficacy is reached after two or three hours. Prosta-
glandin analogues on the other hand attain their maximum
efficacy in seven to eight hours and are more effective when
administered in the evening.
Moreover, prostaglandins are normally administered
once a day, so the same has to apply for a fixed combination.
+is limits doses of timolol, which is usually instilled twice
daily. Two clinical studies comparing the effect of a
latanoprost/timolol fixed combination versus latanoprost
and timolol gel-forming solution unfixed combination in
glaucomatous patients have demonstrated that the con-
comitant solution leads to a larger additional IOP reduction
and lower daytime IOP levels as compared with the fixed
combination, although the fixed combination has some
potential advantages, such as improved compliance, better
adherence, and less exposure to preservatives. +e potential
benefits of fixed combination therapy with latanoprost/
timolol need to be considered against the reduced efficacy
compared with unfixed concomitant therapy [48, 49]. +ese
studies confirmed that fixed combinations are slightly less
effective than concomitant administration of their compo-
nents; in particular, as regards timolol and prostaglandin
agonists, a significant difference in IOP efficacy (1.1mmHg
on average) has been evidenced, which favors the con-
comitant administration of timolol and latanoprost. Overall,
the administration of these two products once daily could
appear preferable: administering prostaglandin in the
evening and 0.1% timolol gel in the morning with a better
efficacy.
2.6. Timolol 0.1% Gel in Ocular Surgery. +e most frequent
complication after ocular surgery is the increase of IOP
level that frequently occurs for various causes including
Table 1: +erapeutic efficacy of 0.1% timolol gel.
Ref. No. ofpatients Methods IOP changes (%)
IOP change
(mmHg) Conclusion





1st line preservative-free 0.1% timolol gel vs 0.1%






1st line or replacement for 0.5% timolol solution
or combination with latanoprost
−27% at 6 month
additional drop







34 111 1st line (53 pts) or replacement for a beta-blocker(58 pts)







1st line (53 pts) or replacement for a poorly









Replacement for latanosprost due to poor
compliance
−30% on latanoprost





37 55 1st line—comparison of 0.1% timolol gel andsolution
IOP reduction 1 to 2mmHg
greater with the gel
formulation (p< 0.05)
Ref.� reference; No.�number; IOP� intraocular pressure; p� p value.
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inflammation, pigment dispersion, viscosurgical device,
greater vascular permeability, or intravitreal injection (IVI)
of anti-VEGF active agents [50, 51].
In a prospective, double-blinded, randomized study, 70
patients who underwent uncomplicated cataract surgery with
phacoemulsification and intraocular lens implantation were
included and divided into three different subgroups: 25 patients
received a single instillation of timolol 0.1% gel, 20 a single
instillation of timolol 0.5% eyedrops, and 25 no treatment. In
conclusion, timolol 0.1% gel was as effective as timolol 0.5%
eyedrops in reducing IOP and in limiting the occurrence of
IOP spikes for up to 24hours after phacoemulsification [50].
In another prospective study, all the patients who un-
derwent an IVI of ranibizumab were randomly divided into
three groups: 50 were not treated with timolol before the IVI,
50 received an instillation of timolol 0.1% gel the evening
before the procedure, and 50 received an instillation of ti-
molol 0.1% gel 2 hours before the IVI. From the results, IOP
spikes are a frequent complication of anti-VEGF IVIs, the
incidence of hypertensive IOP 5minutes after IVI was
significantly less in patients who received timolol 0.1% gel
2 hours before IVI, who also benefited from significantly
greater protection against spikes >40mmHg. +ese findings
suggest that the routine prophylactic use of timolol 0.1% gel
2 hours before IVI is a safe and effective means of preventing
IOP spikes, reducing the need for emergency procedures and
preserving the health of the optic nerve [51].
3. Tolerance
Medical education has held that beta-blocker agents should
be avoided in patients with congestive heart failure and
symptomatic bradycardia as well as more advanced degrees
of heart block; however, they have long played an integral
role in themanagement of cardiovascular disease. It has been
shown how beta-blockers benefit patients with compensated
heart failure, and the American College of Cardiology
recommends that all patients with depressed left ventricular
function, when clinically stable, begin beta-blocker therapy,
regardless of whether or not they had a myocardial in-
farction [5–9,11]. Furthermore, all patients who have suf-
fered myocardial infarction should undergo beta-blocker
therapy for at least 3 years [52].
We have to remember that the literature fails to
support many of the traditionally cited negative effects of
beta-blockers (i.e., intermittent claudication, prolonged
hypoglycemia in type II diabetics, or worsening symptoms
of peripheral vascular disease) and found only supportive
evidence when beta-blockers are administered systemi-
cally (i.e., to reduce individuals’ exercise tolerance and
exercise work output). +ese effects are not simply the
result of a reduction in heart rate or blood pressure during
exercise, such as ophthalmic doses may cause, but are due
to a more complex alteration in energy and electrolyte
metabolism [38–41]. Dickstein et al. demonstrated that
timolol solution, timolol gellan, and betaxolol reduce the
heart rate and systolic arterial blood pressure at baseline
and during exercise, but they found no difference in work
output. In particular, the effect on the heart rate was
statistically more significant than the effect on systolic
arterial blood pressure [53].
+ese data provide additional support for the concepts that
heart rate and blood pressure alone do not account for dif-
ferences in exercise capacity and that ophthalmically admin-
istered doses may be insufficient to affect work output, despite
the statistically significant changes in hemodynamic parameters.
Asthma affects roughly 5% of theWestern population. In
a clinical trial where timolol drops were used in asthmatic
and nonasthmatic patients, there might be an upregulation
of beta-2 receptors after chronic administration, causing
bronchospasm and worsening other chronic obstructive
airway disease or asthma. +us, glaucoma patients with
concomitant pulmonary disease generally should not receive
these agents until further data are available [4–8]. In non-
asthmatic patients, neither 0.5% timolol solution nor 0.1%
timolol gel has noteworthy clinical effects on respiratory
function and blood pressure [42].
In addition, many other side effects have been described
including depression, increased low-density cholesterol
levels, hair loss, sexual impotence, fatigue, confusion, and
disorientation. +e systemic effects of topical beta-blockers
are mainly proportional to timolol plasma levels due to the
nasopharyngeal tract absorption. +e association between
beta-blockers and depression is largely based on published
case reports and short case series, while when clinical trials
and large population-based surveys of patients receiving
systemic beta-blocker therapy were performed, no associ-
ation was found [19].
However, when a single daily administration of 0.1%
timolol gel is used, the systemic bioavailability is largely
under threshold level.
In normolipidemic patients, 0.5% timolol solution
seemed to lower HDL cholesterol levels by 8 to 11% with the
impending increase of LDL+VLDL ratio from 10 up to 24%.
+is adverse effect appears to decrease when timolol in gel
formulation is used, with a significant fall of value from 16 to
18% in lipidic profile formula; this potential effect may be
due to the reduction of systemic absorbance [54].
3.1. Tolerance in Patients with OAG or OH. A prospective,
randomized, investigator-masked, cross-over study in-
vestigated the circadian and blood pressure (BP) re-
duction obtained with timolol maleate 0.5% solution
administered twice daily versus timolol 0.1% in gel-
forming carbomer administered in the morning in pa-
tients with POAG. Following a baseline evaluation, pa-
tients were randomized to receive timolol 0.5% solution or
timolol 0.1% gel for two months and then switched to the
alternative medication for further two months. Ambula-
tory home BP monitoring was measured at baseline and
after each treatment period, systemic and diastolic BP
remained generally unaffected and the calculated diastolic
ocular perfusion pressure was either unaffected.+is study
was undertaken because of old data that topical beta-
blockers may be less efficacious during the night and
may also decrease ocular perfusion due to alterations in
systemic circulatory parameters [27].
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In another study, the authors showed a significant dif-
ference on the drug-induced change in heart rate (in peak
heart rate during the exercise test and after head-up tilt test)
between treatment with 0.5% timolol gel and 0.1% timolol
gel but not between 0.5% aqueous solution and 0.1% timolol
gel treatments although pharmacokinetics curves were
similar between the both timolol 0.5% formulations [42].
3.2. Tolerance in Healthy Volunteers. In a pharmacological
study, heart rate at rest and during exercise was compared in
42 men (aged 55 to 65 years, mean 58.6 years) who were
treated with topical instillation of 0.5% timolol solution
twice a daily and 0.5% timolol gel once a daily. At the end of
administration, an exercise test was performed, the clinical
results showed that reducing the dose administered by half
allowed to reduce significantly adverse effects. No effect on
respiratory function was found in the two groups [53].
4. Quality of Life of Patients
4.1. Chronic Treatment and Ocular Surface Disease. +e
ocular surface system is a very dynamic structure that needs
to be constantly refreshed; as a matter of fact, a lack of water,
lipid, or mucie component of tear film can lead to surface
inflammation and damage to cornea and conjunctiva. Oc-
ular surface diseases are often associated with eyelid disease
and particularly with meibomian gland dysfunction, and
that should be investigated and treated. Unfortunately, not
enough attention is paid to patients who are affected with
both ocular surface disease (OSD) and glaucoma, mostly
when it is necessary to prescribe a IOP-lowering therapy.
Glaucoma disease often requires a treatment for life;
therefore, therapy must be effective and secure with poor
side effects; otherwise, patients will discontinue eyedrops; in
fact, about a quarter of patients complain side effects con-
nected to their glaucoma therapy causing more or less 64%
of reasons for nonadherence to treatment [55–59].
A study performed by 249 French ophthalmologists on
1181 patients treated with antiglaucomatous therapy dem-
onstrated that in 40 to 54% of cases administration of eye-
drops was accompanied by sensation of discomfort or pain,
and 51 to 58% of patients reported at least one symptom
between various instillations (Levrat et al., unpublished data).
A recent retrospective survey performed from 1991 to 2003
showed that patients with severe ocular surface disease more
frequently suffered also from glaucoma, with a prevalence of
67.5% and an incidence of 20.4% in patients with OSD [60].
In chronic topical treatment, the intolerance can be
specifically linked to active ingredients and to preservatives.
Valente and Iester outlined in a review that both compo-
nents can induce intolerance [61].
It has been shown that because of the active compounds
or the preservatives of the topical medication, the long-term
use of antiglaucoma medications induces inflammatory
ocular surface changes, causing a dry eye-like syndrome
[61–68]. +e toxic action of preservatives on the ocular
surface has been largely demonstrated and is related to
concentration, duration of use, and number of instillations
[64–66]. Benzalkonium chloride (BAK), whose efficacy and
toxicity are well known, is the most common preservative in
antiglaucoma drugs [67], but the mechanisms of toxicity in
the ocular surface are complex and not entirely understood.
Generally, it is less frequent to have an immediate al-
lergic reaction with a timolol topic agent than with other
antiglaucoma topical agents; beta-blockers instead can
produce corneal hypoaesthesia and a reduction in tear se-
cretion due to their lipophilic nature and their membrane-
stabilizing activity. +e fall in tear secretion can be clinically
assessed with reduction in tear break-up time (BUT), leading
at the end to dry eye syndrome and superficial punctuate
keratitis [68].
Steuth found that the anesthetic effect of a beta-blocker
applied locally to the surface of the conjunctiva and cornea
could decrease lacrimal gland secretion [69] and then tear
production, probably by systemic and/or local effects of beta-
adrenergic receptor blockade in the lacrimal and/or accessory
palpebral glands. Derous et al. demonstrated that topical beta-
blockers caused thickened conjunctival epithelium, abnormal
keratinization, and loss of goblet cells in the conjunctiva [70].
Herreras et al. showed that 66% of patients who used topical
timolol for an average of 25months and over had abnormal
Schirmer I test and BUT [62].
Sensation of stinging, burning, sand, dryness, watering,
or itching are classical examples of preservative local in-
tolerance; also conjunctival hyperaemia and follicles are
frequent clinical sign in patients using a preservative topical
eye drop. Unfortunately, this type of side effect has an
important consequence on patient’s compliance, which is
very important in long-term therapy for glaucoma; it is clear
that giving a treatment with a preservative-free formula
increases patient’s compliance reducing signs and symptoms
of local disturbance [65].
It is widely demonstrated that symptoms of topical in-
tolerance are two or three times more frequent with oph-
thalmic agents containing a preservative solution than a
preservative-free preparations [65]. A large European study
performed on 9,658 patients treated with ophthalmic beta-
blockers with or without preservative, shown that symptoms
experienced by patients and clinical sign were less common
when administered with unpreserved formula [71].
In patients who switched glaucoma therapy from a
preservative formula to a preservative-free medication was
noted a significant reduction of all ocular symptoms and
signs such as ocular discomfort, sensation of foreign body,
and stinging or burning or sensation of dry eyes.
Preservatives are the principal cause of ocular irritation;
their effect is dose- and time-dependent, and about three-
quarters of ophthalmic medication contains benzalkonium
chloride (BAK) [65, 72–75].
Benzalkonium chloride is one of the most frequently
used ones in ophthalmic medications, and this quaternary
ammonium compound is a detergent that destroys cell
membranes acting as a bactericidial agent but also damaging
conjunctival and corneal surface. +e detergent effect of this
component causes the reduction in number of mucous cells
and changes in transmembrane mucins, which can lead to
dry eye syndrome. BAK at very low concentration is able to
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activate complement system causing the release of numerous
toxic free radicals that stop cell growth, while at normal
concentrations, this compound conduces to irreversible
apoptosis and cell death in 15minutes [76, 77].
+e toxic action of preservatives on the ocular surface,
which has been widely demonstrated, might be related to
preservative concentration, duration of use, and number of
instillations [64–66]. Benzalkonium chloride promotes acti-
vation of lipooxygenase and synthesis and secretion of ei-
cosanoids, inflammatory mediators, andmany cytokines such
as interleukin (IL)-la, tumor necrosis factor-α, IL-8, and IL-
10, resulting in irritation, delayed hypersensitivity, and al-
lergic reactions [78]. Green et al. showed that BAK has a very
slow turnover in the eye, being retained in ocular tissues for
up to 48 hours after administration of a single drop [79].
Toxicity was delayed and prolonged, probably due to in-
corporation and persistence of BAK molecules in cell
membranes. +ree mechanisms of BAK toxicity have been
described: a detergent effect, causing loss of tear film stability;
direct damage to the corneal and conjunctival epithelium; and
immunoallergic reaction [80]. +e ocular cytotoxicity of BAK
has been demonstrated in many in vitro and in vivo models
[65]. Manni et al. compared patients treated with preserved
timolol with patients treated with preservative-free timolol
and found a significantly higher level of IL-1β in the preserved
timolol treated group [81]. Noecker et al. showed that topical
hypotonic drugs containing low preservative concentrations
were associated with less inflammatory infiltrate in the rabbit
conjunctiva [82].
Several clinical studies on humans confirm these labo-
ratory results. Pisella et al. found an increase of the frequency
of eye irritation in glaucoma patients who use preserved eye
drops. Signs and symptoms were correlated with the number
of preserved eye drops used by patients [65]. Baudouin
confirmed that the frequency of dry eye-like symdrome
symptoms and signs were higher in patients treated with
preserved than preservative-free eye drops, and the change
from preserved to preservative-free preparation was associated
with a significant decrease in ocular surface irritation [83].
In patients treated for a long period with antiglaucoma
topical agents, inflammatory reaction is very common with
signs of macrophages infiltration over the conjunctiva and
expression of antigenes which is essential in the immune
response of cells [84]. In studies performed with confocal
microscopy comparing preservative-free 0.1% timolol in gel
and other BAK-preserved eye drops, it was demonstrated
that conjunctival morphology, epithelial layer, and goblet
cells profile were unaffected for preservative-free timolol
formula [85].
Inflammation over conjunctiva fatally causes damages to
epithelium, keratinization, and loss of mucus cell and fibrous
and scar tissues, and this cascade can be avoided using a
preservative-free agents. For these side effects, it is essential
for glaucomatous patients to avoid conjunctiva’s in-
flammation to give trabeculectomy a chance of success and
to maintain a good quality of life for a good compliance and
adherence to therapy.
Minimally invasive techniques, such as confocal mi-
croscopy, are preferable for in vivo assessment of the
histopathology of many ocular surface diseases [86–89] and
for investigating the toxic effects of chronic glaucoma
therapy [85].
Using in vivo confocal microscopy (IVCM) (HRT II
Cornea Module; Heidelberg Engineering GmbH, Heidel-
berg, Germany), Frezzotti et al. showed that during the 1-
year follow-up, no signs of ocular surface were found in both
controls and patients treated with preservative-free timolol,
while BAK-preserved eye drops were associated with a lower
goblet cell density and epithelial irregularity which are signs
of ocular surface inflammation [85]. Furthermore, in a
different study, these clinical signs due to BAK have been
found just after 6months of treatment [66]. However, these
are short-term intervals when compared with the chronicity
of the disease.
Overall, the findings of different studies which compared
preservative to preservative-free drops seem clinically rel-
evant considering that goblet cells are responsible for mucin
production, and mucins are fundamental to guarantee the
adhesion of tear film to epithelia, whose homogeneity is a
sign of health [86]. +e relatively small changes of IVCM are
often associated to relevant changes of signs and symptoms
of ocular surface disfunction [90–92], a fact that is evenmore
relevant if we consider that patients with glaucoma are very
frequently exposed to multiple treatments. As the iatrogenic
damage in glaucoma is mostly due to preservatives, mini-
mizing their administration is an impelling need as Noecker
and colleagues showed in the rabbit conjunctiva [82].
In conclusion, in many clinical studies, in patients with
glaucoma, the use of preserved eye drops increases the
frequency of ocular surface irritation, in a dose-dependent
manner [65, 82], and the switch from preserved to
preservative-free formulations induces recovery from eye
irritation [82] as laboratory results confirmed.
4.2. Patient’s Compliance to 7erapy. A meta-analysis study
performed on 1,256 patients with OAG or OH treated either
with latanoprost or timolol shown that up to 18% of patients
developed iris pigmentation and conjunctival hyperaemia,
these sides effects were rarer with patient treated with timolol.
Another frequent side effect of prostaglandin found was
eyelash hypertrichosis that can be disturbing for patients be-
cause eyelash may become longer and thicker with an unusual
growth, together with a increased of inflammation stimulated
by proinflammatory arachidonate cascade (e.g., uveitis, iritis,
and macular oedema), less frequently [93]. However, we have
to remember that timolol causes iris pigmentation in about 30
% patients after four years of treatment and could affect up to
85% of patients with mixed color irides [94].
Glaucoma patients can lose quality of life (QoL) for
several reasons: the diagnosis itself, the functional loss, the
inconvenience of the treatment, the side effects of the
treatment, and the cost of the treatment [59]. QoL can be
measured by questionnaires, but it is also dependent on
subjective evaluation by the patient. In this study, we in-
troduced a questionnaire to better evaluate the visual quality
and symptoms and the quality of life. Most of the both ocular
surface and general symptom questions showed a
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statistically significant improvement in 3months of follow-
up. Also, the revised Mills and Drance’s questionnaire or
Viswanathan et al.’s questionnaire was used in this study
because it has been shown to be the most sensitive one in
glaucomatous patients [59], but the results have been used
for a different study and not presented in this manuscript.
Iester et al. showed an improvement of the ocular surface
after the treatment was changed and preservative-free beta-
blocker used (Table 2). Besides, in the timogel drop, there is
also an artificial tear, which could help the improvement of
the ocular surface both for clinical signs and symptoms
(Table 2); this positive effect was seen also for both break-up
time and Schirmer’s test [95]. In addition to this, the
preservative-free formula of 0.1% timolol was better tolerated
by patients and improved the quality of life (QoL) reducing
dryness, hyperaemia, follicular hyperplasia, and foreign body
sensation. Considering that adherence to treatment is pro-
portional to QoL in glaucoma, it is largely preferable in these
patients to use a preservative-free formula [95]. (Table 3)
In a different study, 82% of patients were satisfied or very
satisfied with timogel vs 61% with previous treatment, and
the difference was statistically significant (p< 0.01) [96].
+ese data are confirmed by another following study that
concluded that chronic exposure to BAK-preserved topical
IOP-loweringmedicationwas associatedwith adverse effects for
the ocular surface; instead, a treatment with a BAK-free gel
formulation with timolol 0.1% resulted in a measurable im-
provement in TBUT, Schirmer test result, and OSD index and
in the quality of life of glaucoma patients. It has been also
demonstrated that the use of preservative-free timolol 0.1% gel
maintained the efficacy of IOP and reduced signs and symp-
toms in almost all glaucomatous patients treated with a pre-
served latanoprost formula with signs of local intolerance [44].
In conclusion, preservative-free timolol 0.1 treatment
maintained IOP at the same level of the other beta-blockers,
but it was better tolerated in patients having signs or
symptoms while on preserved beta-blockers. Preservative-
free treatment improved the quality of life reducing dryness,
hyperaemia, follicular hyperplasia, and foreign body sen-
sation, probably for the lack of BAK and the presence of an
artificial tear in the medication bottle. +e once-daily dosing
improves compliance and adherence.
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niums quaternaires sur une lignée de cellules conjonctivales
humaines,” Journal Français d’Ophtalmologie, vol. 22, no. 9,
pp. 950–958, 1999.
[77] M. Iester, F. Oddone, P. Fogagnolo, P. Frezzotti, M. Figus, and
the Confocal Microscopy Study Group, “Changes in the
morphological and functional patterns of the ocular surface in
patients treated with prostaglandin analogues after the use of
TSP 0.5% preservative-free eyedrop: a prospective, multi-
center study,” Ophthalmic Research, vol. 51, no. 3, pp. 146–
152, 2014.
[78] M. De Saint Jean, F. Brignole, A. F. Bringuier, A. Bauchet,
G. Feldmann, and C. Baudouin, “Effects of benzalkonium
chloride on growth and survival of Chang conjunctival cells,”
Investigative Ophthalmology and Visual Science, vol. 40,
pp. 619–630, 1999.
[79] K. Green, M. C. Jack, L. Cheeks, M. C. Ruth, M. Wilson, and
A. Zehir, “Detergent penetration into young and adult rabbit
eyes: comparative pharmacokinetics,” Journal of Toxicology:
Cutaneous and Ocular Toxicology, vol. 6, no. 2, pp. 89–107,
1987.
[80] R. W. Yee, “+e effect of drop vehicle on the efficacy and side
effects of topical glaucoma therapy: a review,” Current
Opinion in Ophthalmology, vol. 18, no. 2, pp. 134–139, 2007.
[81] G. Manni, M. Centofanti, F. Oddone, M. Parravano, and
M. G. Bucci, “Interleukin-1β tear concentration in glau-
comatous and ocular hypertensive patients treated with
preservative-free nonselective beta-blockers,” American
Journal of Ophthalmology, vol. 139, no. 1, pp. 72–77, 2005.
[82] R. J. Noecker, L. A. Herrygers, and R. Anwaruddin, “Corneal
and conjunctival changes caused by commonly used glau-
coma medications,” Cornea, vol. 23, no. 5, pp. 490–496,
2004.
[83] C. Baudouin, “Allergic reaction to topical eyedrops,” Current
Opinion in Allergy and Clinical Immunology, vol. 5, no. 5,
pp. 459–463, 2005.
[84] L. Bensoussan, C. Blondin, C. Baudouin et al., “Flow cyto-
metric analysis of HLA-DR, IL-6 and IL-8 expression by
conjunctival epithelial cells from patients with prolonged
topical antiglaucoma treatments,” Journal Français d’Oph-
talmologie, vol. 26, no. 8, pp. 782–789, 2003.
[85] P. Frezzotti, P. Fogagnolo, G. Haka et al., “In vivo confocal
microscopy of conjunctiva in preservative-free timolol 0.1%
gel formulation therapy for glaucoma,” Acta Oph-
thalmologica, vol. 92, no. 2, pp. e133–e140, 2014.
[86] L. Mastropasqua, M. Nubile, M. Lanzini, P. Carpineto,
L. Toto, and M. Ciancaglini, “Corneal and conjunctival
manifestations in Fabry disease: in vivo confocal microscopy
study,” American Journal of Ophthalmology, vol. 141, no. 4,
pp. 709–709.e11, 2006.
[87] G.Martone, P. Frezzotti, G. M. Tosi et al., “An in vivo confocal
microscopy analysis of effects of topical antiglaucoma therapy
with preservative on corneal innervation and morphology,”
American Journal of Ophthalmology, vol. 147, no. 4,
pp. 725–735.e1, 2009.
[88] Q.-h. Le, W.-t. Wang, J.-x. Hong et al., “An in vivo confocal
microscopy and impression cytology analysis of goblet cells
in patients with chemical burns,” Investigative Opthal-
mology and Visual Science, vol. 51, no. 3, pp. 1397–1400,
2010.
[89] W. Zhu, J. Hong, T. Zheng, Q. Le, J. Xu, and X. Sun, “Age-
related changes of human conjunctiva on in vivo confocal
microscopy,” British Journal of Ophthalmology, vol. 94, no. 11,
pp. 1448–1453, 2010.
[90] J. D. Nelson, V. R. Havener, and J. D. Cameron, “Cellulose
acetate impressions of the ocular surface,” Archives of Oph-
thalmology, vol. 101, no. 12, pp. 1869–1872, 1983.
[91] J. E. Moore, J. E. Graham, E. A. Goodall et al., “Concordance
between common dry eye diagnostic tests,” British Journal of
Ophthalmology, vol. 93, no. 1, pp. 66–72, 2009.
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[93] G. Holló, “+e side effects of the prostaglandin analogues,”
Expert Opinion on Drug Safety, vol. 6, no. 1, pp. 45–52, 2007.
[94] W. Y. Zhang, A. L. Po, H. S. Dua, and A. Azuara-Blanco,
“Meta-analysis of randomised controlled trials comparing
latanoprost with timolol in the treatment of patients with
open angle glaucoma or ocular hypertension,” British Journal
of Ophthalmology, vol. 85, no. 8, pp. 983–990, 2001.
[95] M. Iester, S. Telani, P. Frezzotti et al., “Ocular surface changes
in glaucomatous patients treated with and without
Journal of Ophthalmology 11
preservatives beta-blockers,” Journal of Ocular Pharmacology
and 7erapeutics, vol. 30, no. 6, pp. 476–481, 2014.
[96] T. Rolle, D. Curto, C. Alovisi et al., “Timogel vs timolol 0.5%
ophthalmic solution: efficacy safety and acceptance,” Euro-
pean Journal of Ophthalmology, vol. 22, no. 1, pp. 28–33, 2012.
















































































Submit your manuscripts at
www.hindawi.com
